NAPB

Summary

NAPB (NSF attachment protein beta, HGNC:15751) is a protein-coding gene on chromosome 20p11.21, encoding Beta-soluble NSF attachment protein (Q9H115). Required for vesicular transport between the endoplasmic reticulum and the Golgi apparatus.

This gene encodes a member of the soluble N-ethyl-maleimide-sensitive fusion attachment protein (SNAP) family. SNAP proteins play a critical role in the docking and fusion of vesicles to target membranes as part of the 20S NSF-SNAP-SNARE complex. This gene encodes the SNAP beta isoform which has been shown to be preferentially expressed in brain tissue. The encoded protein also interacts with the GluR2 α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptor subunit C-terminus and may play a role as a chaperone in the molecular processing of the AMPA receptor.

Source: NCBI Gene 63908 — RefSeq curated summary.

At a glance

• Gene–disease (curated): developmental and epileptic encephalopathy 107 (Definitive, GenCC)
• Clinical variants (ClinVar): 44 total — 3 pathogenic
• MANE Select transcript: NM_022080

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:15751
Approved symbol	NAPB
Name	NSF attachment protein beta
Location	20p11.21
Locus type	gene with protein product
Status	Approved
Aliases	SNAP-BETA, SNAPB
Ensembl gene	ENSG00000125814
Ensembl biotype	protein_coding
OMIM	611270
Entrez	63908

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 10 protein_coding, 3 protein_coding_CDS_not_defined

ENST00000377026, ENST00000398425, ENST00000432543, ENST00000468128, ENST00000472855, ENST00000487502, ENST00000617876, ENST00000856932, ENST00000856933, ENST00000963019, ENST00000963020, ENST00000963021, ENST00000963022

RefSeq mRNA: 4 — MANE Select: NM_022080 NM_001283018, NM_001283020, NM_001283026, NM_022080

CCDS: CCDS13152, CCDS63241, CCDS63242, CCDS74710

Canonical transcript exons

ENST00000377026 — 11 exons

Exon	Start	End
ENSE00000859452	23395139	23395185
ENSE00000859458	23379445	23379495
ENSE00001918222	23374522	23377486
ENSE00001944089	23421305	23421488
ENSE00003464611	23389946	23390030
ENSE00003466421	23394922	23394999
ENSE00003471825	23390209	23390264
ENSE00003487621	23397072	23397188
ENSE00003499945	23402993	23403072
ENSE00003600815	23379867	23379935
ENSE00003654748	23381213	23381317

Expression profiles

Bgee: expression breadth ubiquitous, 245 present calls, max score 99.96.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 17.4029 / max 1191.3500, expressed in 1711 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
186700	17.4029	1711

Top tissues by expression

252 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
middle temporal gyrus	UBERON:0002771	99.96	gold quality
Brodmann (1909) area 23	UBERON:0013554	99.87	gold quality
endothelial cell	CL:0000115	99.86	gold quality
pons	UBERON:0000988	99.62	gold quality
superior frontal gyrus	UBERON:0002661	99.61	gold quality
cerebellar vermis	UBERON:0004720	99.49	gold quality
lateral nuclear group of thalamus	UBERON:0002736	99.48	gold quality
substantia nigra pars compacta	UBERON:0001965	99.42	gold quality
parietal lobe	UBERON:0001872	99.40	gold quality
postcentral gyrus	UBERON:0002581	99.38	gold quality
superior vestibular nucleus	UBERON:0007227	99.33	gold quality
Brodmann (1909) area 46	UBERON:0006483	99.27	gold quality
entorhinal cortex	UBERON:0002728	99.13	gold quality
occipital lobe	UBERON:0002021	99.06	gold quality
primary visual cortex	UBERON:0002436	99.06	gold quality
substantia nigra pars reticulata	UBERON:0001966	99.03	gold quality
medulla oblongata	UBERON:0001896	98.72	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	98.72	gold quality
Brodmann (1909) area 9	UBERON:0013540	98.72	gold quality
lateral globus pallidus	UBERON:0002476	98.71	gold quality
ventral tegmental area	UBERON:0002691	98.54	gold quality
prefrontal cortex	UBERON:0000451	98.51	gold quality
frontal cortex	UBERON:0001870	98.41	gold quality
cerebellum	UBERON:0002037	98.21	gold quality
cerebellar cortex	UBERON:0002129	98.13	gold quality
cerebellar hemisphere	UBERON:0002245	98.09	gold quality
cerebral cortex	UBERON:0000956	98.03	gold quality
temporal lobe	UBERON:0001871	98.01	gold quality
neocortex	UBERON:0001950	97.91	gold quality
dorsal root ganglion	UBERON:0000044	97.83	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-HCAD-35	yes	41.78
E-GEOD-137537	yes	14.11
E-GEOD-84465	yes	7.32
E-ANND-3	no	5.29

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

103 targeting NAPB, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-3064-3P	100.00	70.09	1254
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-3617-3P	99.98	67.86	918
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394

Literature-anchored findings (GeneRIF, showing 2)

• A novel NAPB splicing mutation identified by Trio-based exome sequencing is associated with early-onset epileptic encephalopathy. (PMID:33189936)
• NAPB and developmental and epileptic encephalopathy: Description of the electroclinical profile associated with a novel pathogenic variant. (PMID:37014259)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	napba	ENSDARG00000013669
danio_rerio	napbb	ENSDARG00000069101
mus_musculus	Napb	ENSMUSG00000027438
rattus_norvegicus	Napb	ENSRNOG00000004753
drosophila_melanogaster	alphaSnap	FBGN0250791
caenorhabditis_elegans		WBGENE00017016

Paralogs (2): NAPA (ENSG00000105402), NAPG (ENSG00000134265)

Protein

Protein identifiers

Beta-soluble NSF attachment protein — Q9H115 (reviewed: Q9H115)

Alternative names: N-ethylmaleimide-sensitive factor attachment protein beta

All UniProt accessions (2): Q9H115, A0A087WZQ7

UniProt curated annotations — full annotation on UniProt →

Function. Required for vesicular transport between the endoplasmic reticulum and the Golgi apparatus.

Subunit / interactions. Interacts with PRKCABP, and disrupts the interaction between GRIA2 and PRKCABP, leading to the internalization of GRIA2.

Subcellular location. Membrane.

Disease relevance. Developmental and epileptic encephalopathy 107 (DEE107) [MIM:620033] A form of epileptic encephalopathy, a heterogeneous group of early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE107 is an autosomal recessive form characterized by onset of seizures in the first months of life. Affected individuals have severe global developmental delay, profound intellectual disability, progressive microcephaly, and hypotonia. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the SNAP family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9H115-1	1	yes
Q9H115-2	2
Q9H115-3	3

RefSeq proteins (4): NP_001269947, NP_001269949, NP_001269955, NP_071363* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000744	NSF_attach	Family
IPR011990	TPR-like_helical_dom_sf	Homologous_superfamily

Pfam: PF14938

UniProt features (7 total): splice variant 3, sequence variant 3, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9H115-F1	89.55	0.68

Function

Pathways and Gene Ontology

Reactome pathways

14 pathways

ID	Pathway
R-HSA-204005	COPII-mediated vesicle transport
R-HSA-6807878	COPI-mediated anterograde transport
R-HSA-6811434	COPI-dependent Golgi-to-ER retrograde traffic
R-HSA-6811438	Intra-Golgi traffic
R-HSA-6811440	Retrograde transport at the Trans-Golgi-Network
R-HSA-199977	ER to Golgi Anterograde Transport
R-HSA-199991	Membrane Trafficking
R-HSA-392499	Metabolism of proteins
R-HSA-446203	Asparagine N-linked glycosylation
R-HSA-5653656	Vesicle-mediated transport
R-HSA-597592	Post-translational protein modification
R-HSA-6811442	Intra-Golgi and retrograde Golgi-to-ER traffic
R-HSA-8856688	Golgi-to-ER retrograde transport
R-HSA-948021	Transport to the Golgi and subsequent modification

MSigDB gene sets: 181 (showing top): GOBP_INTRACELLULAR_PROTEIN_TRANSPORT, GOBP_NEUROTRANSMITTER_TRANSPORT, GOBP_VESICLE_MEDIATED_TRANSPORT, REACTOME_MEMBRANE_TRAFFICKING, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, GGAMTNNNNNTCCY_UNKNOWN, AAAYRNCTG_UNKNOWN, CAGCTG_AP4_Q5, GOBP_CELL_CELL_SIGNALING, GOBP_EXOCYTOSIS, IRF1_Q6, TGTGTGA_MIR377, GOBP_SECRETION, GOBP_REGULATION_OF_PROTEIN_CONTAINING_COMPLEX_ASSEMBLY, TGANTCA_AP1_C

GO Biological Process (6): intracellular protein transport (GO:0006886), regulation of synaptic vesicle priming (GO:0010807), synaptic transmission, glutamatergic (GO:0035249), SNARE complex disassembly (GO:0035494), protein transport (GO:0015031), vesicle-mediated transport (GO:0016192)

GO Molecular Function (3): soluble NSF attachment protein activity (GO:0005483), syntaxin binding (GO:0019905), protein binding (GO:0005515)

GO Cellular Component (4): synaptobrevin 2-SNAP-25-syntaxin-1a complex (GO:0070044), extracellular exosome (GO:0070062), glutamatergic synapse (GO:0098978), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-9 pathways:

Category	Pathways
Intra-Golgi and retrograde Golgi-to-ER traffic	3
ER to Golgi Anterograde Transport	2
Membrane Trafficking	2
Golgi-to-ER retrograde transport	1
Transport to the Golgi and subsequent modification	1
Vesicle-mediated transport	1
Post-translational protein modification	1
Metabolism of proteins	1
Asparagine N-linked glycosylation	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intracellular protein localization	2
transport	2
protein transport	1
intracellular transport	1
synaptic vesicle priming	1
regulation of protein-containing complex assembly	1
chemical synaptic transmission	1
vesicle-mediated transport	1
protein-containing complex disassembly	1
establishment of protein localization	1
cellular process	1
protein-macromolecule adaptor activity	1
SNARE binding	1
binding	1
SNARE complex	1
extracellular vesicle	1
synapse	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1108 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NAPB	SNAP23	O00161	708
NAPB	SNAP25	P13795	692
NAPB	STX4	Q12846	691
NAPB	NSF	P46459	673
NAPB	VAMP8	Q9BV40	608
NAPB	NAPG	Q99747	532
NAPB	STX1B	P61266	493
NAPB	VAMP7	P51809	488
NAPB	STX3	Q13277	463
NAPB	F8A2	P23610	448
NAPB	STX6	O43752	441
NAPB	VAMP2	P19065	431
NAPB	VAMP3	Q15836	428
NAPB	VAMP1	P23763	384
NAPB	ACTR2	P61160	364

IntAct

162 interactions, top by confidence:

A	B	Type	Score
STX11	SNAP23	psi-mi:“MI:0914”(association)	0.900
NAPB	STX3	psi-mi:“MI:0915”(physical association)	0.870
STX3	NAPB	psi-mi:“MI:0915”(physical association)	0.870
NAPA	SNAP23	psi-mi:“MI:0914”(association)	0.780
STX6	NAPB	psi-mi:“MI:0915”(physical association)	0.740
NAPB	STX6	psi-mi:“MI:0915”(physical association)	0.740
NAPB	STX4	psi-mi:“MI:0915”(physical association)	0.720
STX5	NAPB	psi-mi:“MI:0915”(physical association)	0.720
NAPB	STX5	psi-mi:“MI:0915”(physical association)	0.720
STX4	NAPB	psi-mi:“MI:0915”(physical association)	0.720
STX1A	NAPB	psi-mi:“MI:0915”(physical association)	0.670
STX6	GOSR2	psi-mi:“MI:0914”(association)	0.670
STX7	SNAP23	psi-mi:“MI:0914”(association)	0.640
STX12	SNAP23	psi-mi:“MI:0914”(association)	0.640
SNAP23	NAPB	psi-mi:“MI:0915”(physical association)	0.560
NAPB	STX16	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (74): NAPB (Two-hybrid), NAPB (Two-hybrid), NAPB (Two-hybrid), NAPB (Two-hybrid), NAPB (Two-hybrid), NAPB (Two-hybrid), NAPB (Two-hybrid), NAPB (Two-hybrid), NAPB (Affinity Capture-MS), NAPB (Affinity Capture-MS), NAPB (Affinity Capture-MS), NAPB (Affinity Capture-MS), NAPB (Affinity Capture-MS), NAPB (Two-hybrid), NAPB (Affinity Capture-MS)

ESM2 similar proteins: A0JN39, A7Y521, B0BN93, B5DGH9, D2SW95, F1LMZ8, F1QGH9, F6P3G4, F6XBL2, O00231, O43242, O88544, P14685, P23514, P28663, P35606, P53618, P60228, P60229, P84169, Q05AY2, Q06364, Q1LUA8, Q2KI42, Q2KJ46, Q3B8M3, Q3SZA0, Q3T102, Q4R5E6, Q4R6G8, Q5E964, Q5R648, Q5R8K9, Q5R922, Q5ZIA5, Q5ZLA5, Q641X8, Q68FS2, Q6DRI1, Q6NWV3

Diamond homologs: O90758, P28663, P54920, P54921, P81125, P81126, P85969, P93798, Q23983, Q9DB05, Q9H115, Q9J5J0, P32602, P78603, Q54NP6, Q75D68, Q9LXZ5, Q9M5P8, Q9P4D0, Q9P4X4, Q9P6A5, Q9SPE6

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 67 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Intra-Golgi traffic	7	38.7×	4e-08
Retrograde transport at the Trans-Golgi-Network	5	23.4×	9e-05
Intra-Golgi and retrograde Golgi-to-ER traffic	8	17.8×	9e-07
COPII-mediated vesicle transport	5	17.4×	4e-04
COPI-mediated anterograde transport	5	11.7×	2e-03
Membrane Trafficking	14	11.0×	4e-09
Vesicle-mediated transport	14	10.4×	4e-09

GO biological processes:

GO term	Partners	Fold	FDR
obsolete vesicle docking	13	153.2×	3e-24
vesicle fusion	10	92.6×	1e-15
membrane fusion	5	48.0×	5e-06
exocytosis	8	18.7×	1e-06
intracellular protein transport	14	14.0×	1e-10

Disease & clinical

Clinical variants and AI predictions

ClinVar

44 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	3
Likely pathogenic	0
Uncertain significance	29
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (3)

Variant ID	HGVS	Classification
234936	NM_022080.3(NAPB):c.479C>A (p.Ser160Ter)	Pathogenic
2572575	NM_022080.3(NAPB):c.333C>A (p.Tyr111Ter)	Pathogenic
984717	NM_022080.3(NAPB):c.173G>A (p.Trp58Ter)	Pathogenic

SpliceAI

0 predictions. Top by Δscore:

AlphaMissense

1990 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
20:23390264:C:G	A141P	1.000
20:23394959:G:T	A128E	1.000
20:23394980:G:T	A121D	1.000
20:23394983:G:T	A120E	1.000
20:23397105:C:G	A88P	1.000
20:23397122:G:T	A82D	1.000
20:23403012:C:A	K53N	1.000
20:23403012:C:G	K53N	1.000
20:23377421:T:A	K284N	0.999
20:23377421:T:G	K284N	0.999
20:23377428:C:G	R282P	0.999
20:23377431:A:G	L281P	0.999
20:23379491:A:G	L247P	0.999
20:23379885:T:A	R239S	0.999
20:23379885:T:G	R239S	0.999
20:23379886:C:A	R239I	0.999
20:23379886:C:G	R239T	0.999
20:23381243:G:C	C212W	0.999
20:23381245:A:G	C212R	0.999
20:23381247:A:G	L211P	0.999
20:23381253:G:T	A209D	0.999
20:23381254:C:G	A209P	0.999
20:23381313:C:T	G189E	0.999
20:23389965:G:T	A181D	0.999
20:23389966:C:G	A181P	0.999
20:23389989:G:T	A173D	0.999
20:23390001:G:T	A169E	0.999
20:23390026:C:G	A161P	0.999
20:23390225:C:G	G154R	0.999
20:23390225:C:T	G154R	0.999

dbSNP variants (sampled 300 via entrez): RS1000057573 (20:23422870 C>T), RS1000135428 (20:23417327 A>C), RS1000153668 (20:23374408 G>A), RS1000183373 (20:23399150 C>CAGAGCA), RS1000194876 (20:23417900 A>G), RS1000241653 (20:23387927 G>A), RS1000325881 (20:23392342 C>A,T), RS1000373254 (20:23405636 A>C), RS1000429935 (20:23422671 A>G), RS1000467738 (20:23405968 C>T), RS1000519003 (20:23397676 A>C), RS1000708201 (20:23411676 C>A,T), RS1000725035 (20:23393020 C>A,G,T), RS1000778764 (20:23393340 A>G), RS1000845444 (20:23386487 C>G,T)

Disease associations

OMIM: gene MIM:611270 | disease phenotypes: MIM:620033, MIM:308350

GenCC curated gene-disease

Disease	Classification	Inheritance
developmental and epileptic encephalopathy 107	Definitive	Autosomal recessive

Mondo (3): prostate cancer (MONDO:0008315), developmental and epileptic encephalopathy 107 (MONDO:0031055), developmental and epileptic encephalopathy, 1 (MONDO:0010632)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

23 total (human), top 23 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases abundance, increases expression	4
GSK-J4	increases expression	1
triphenyl phosphate	affects expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
nickel sulfate	decreases expression	1
4-aminophenylarsenoxide	affects binding, decreases reaction	1
di-n-butylphosphoric acid	affects expression	1
abrine	increases expression	1
Sunitinib	increases expression	1
Arsenic Trioxide	affects binding, decreases reaction	1
Air Pollutants	increases abundance, increases expression	1
Arsenic	increases abundance, increases expression	1
Ethyl Methanesulfonate	increases expression	1
Formaldehyde	decreases expression	1
Ivermectin	decreases expression	1
Lead	affects expression	1
Methyl Methanesulfonate	increases expression	1
Quercetin	increases expression	1
Rotenone	decreases expression	1
Vincristine	increases expression	1
Cyclosporine	increases expression	1
Asbestos, Crocidolite	decreases expression	1
Particulate Matter	increases abundance, increases expression	1

Cellosaurus cell lines

5 cell lines: 5 induced pluripotent stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_C1VV	QBRIi014-A	Induced pluripotent stem cell	Male
CVCL_C1VW	QBRIi015-A	Induced pluripotent stem cell	Male
CVCL_C1VX	QBRIi016-A	Induced pluripotent stem cell	Male
CVCL_C1VY	QBRIi017-A	Induced pluripotent stem cell	Female
CVCL_C1VZ	QBRIi018-A	Induced pluripotent stem cell	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer